The global antibody drug conjugates market size was USD 10.30 billion in 2023, estimated at USD 11.43 billion in 2024 and is anticipated to reach around USD 31.96 billion by 2034, expanding at a CAGR of 10.83% from 2024 to 2034.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Antibody Drug Conjugates Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Antibody Drug Conjugates Market, by Application, 2024-2034
8.1.1. Blood Cancer
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Breast Cancer
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Urothelial Cancer
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. Bladder Cancer
8.1.4.1. Market Revenue and Forecast (2021-2034)
9.1. Antibody Drug Conjugates Market, by Technology, 2024-2034
9.1.1. Cleavable
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Non-cleavable
9.1.2.1. Market Revenue and Forecast (2021-2034)
10.1. North America
10.1.1. Market Revenue and Forecast, by Application (2021-2034)
10.1.2. Market Revenue and Forecast, by Technology (2021-2034)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Application (2021-2034)
10.1.3.2. Market Revenue and Forecast, by Technology (2021-2034)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Application (2021-2034)
10.1.4.2. Market Revenue and Forecast, by Technology (2021-2034)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Application (2021-2034)
10.2.2. Market Revenue and Forecast, by Technology (2021-2034)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Application (2021-2034)
10.2.3.2. Market Revenue and Forecast, by Technology (2021-2034)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Application (2021-2034)
10.2.4.2. Market Revenue and Forecast, by Technology (2021-2034)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Application (2021-2034)
10.2.5.2. Market Revenue and Forecast, by Technology (2021-2034)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Application (2021-2034)
10.2.6.2. Market Revenue and Forecast, by Technology (2021-2034)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Application (2021-2034)
10.3.2. Market Revenue and Forecast, by Technology (2021-2034)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Application (2021-2034)
10.3.3.2. Market Revenue and Forecast, by Technology (2021-2034)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Application (2021-2034)
10.3.4.2. Market Revenue and Forecast, by Technology (2021-2034)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Application (2021-2034)
10.3.5.2. Market Revenue and Forecast, by Technology (2021-2034)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Application (2021-2034)
10.3.6.2. Market Revenue and Forecast, by Technology (2021-2034)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Application (2021-2034)
10.4.2. Market Revenue and Forecast, by Technology (2021-2034)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Application (2021-2034)
10.4.3.2. Market Revenue and Forecast, by Technology (2021-2034)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Application (2021-2034)
10.4.4.2. Market Revenue and Forecast, by Technology (2021-2034)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Application (2021-2034)
10.4.5.2. Market Revenue and Forecast, by Technology (2021-2034)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Application (2021-2034)
10.4.6.2. Market Revenue and Forecast, by Technology (2021-2034)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Application (2021-2034)
10.5.2. Market Revenue and Forecast, by Technology (2021-2034)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Application (2021-2034)
10.5.3.2. Market Revenue and Forecast, by Technology (2021-2034)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Application (2021-2034)
10.5.4.2. Market Revenue and Forecast, by Technology (2021-2034)
11.1. Takeda Pharmaceutical Company Limited
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Pfizer Inc
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. GlaxoSmithKline Plc
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. AstraZeneca
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Seagen Inc
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. ADC Therapeutics
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Gilead Sciences Inc
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. F. Hoffmann-La Roche Ltd
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample